vs
LOUISIANA-PACIFIC CORP（LPX）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
LOUISIANA-PACIFIC CORP的季度营收约是Bio-Techne的1.8倍（$566.0M vs $311.4M），Bio-Techne净利率更高（16.4% vs -1.4%，领先17.8%），Bio-Techne同比增速更快（-1.5% vs -16.9%），过去两年Bio-Techne的营收复合增速更高（1.3% vs -11.6%）
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
LPX vs TECH — 直观对比
营收规模更大
LPX
是对方的1.8倍
$311.4M
营收增速更快
TECH
高出15.4%
-16.9%
净利率更高
TECH
高出17.8%
-1.4%
两年增速更快
TECH
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $566.0M | $311.4M |
| 净利润 | $-8.0M | $51.0M |
| 毛利率 | 15.0% | 66.9% |
| 营业利润率 | -1.6% | 24.2% |
| 净利率 | -1.4% | 16.4% |
| 营收同比 | -16.9% | -1.5% |
| 净利润同比 | -112.9% | 126.0% |
| 每股收益（稀释后） | $-0.12 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPXTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $566.0M | $295.9M | ||
| Q3 25 | $663.0M | — | ||
| Q2 25 | $755.0M | $317.0M | ||
| Q1 25 | $724.0M | $316.2M | ||
| Q4 24 | $681.0M | $297.0M | ||
| Q3 24 | $722.0M | $289.5M | ||
| Q2 24 | $814.0M | $306.1M |
净利润LPXTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-8.0M | $38.0M | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $54.0M | $-17.7M | ||
| Q1 25 | $91.0M | $22.6M | ||
| Q4 24 | $62.0M | $34.9M | ||
| Q3 24 | $90.0M | $33.6M | ||
| Q2 24 | $160.0M | $40.6M |
毛利率LPXTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | 15.0% | 64.6% | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 23.6% | 62.7% | ||
| Q1 25 | 27.2% | 67.9% | ||
| Q4 24 | 23.8% | 65.3% | ||
| Q3 24 | 26.7% | 63.2% | ||
| Q2 24 | 32.3% | 66.4% |
营业利润率LPXTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | -1.6% | 18.4% | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 10.6% | -7.5% | ||
| Q1 25 | 16.6% | 12.2% | ||
| Q4 24 | 11.0% | 16.0% | ||
| Q3 24 | 16.1% | 13.8% | ||
| Q2 24 | 23.8% | 15.0% |
净利率LPXTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | -1.4% | 12.8% | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 7.2% | -5.6% | ||
| Q1 25 | 12.6% | 7.1% | ||
| Q4 24 | 9.1% | 11.7% | ||
| Q3 24 | 12.5% | 11.6% | ||
| Q2 24 | 19.7% | 13.3% |
每股收益（稀释后）LPXTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.12 | $0.24 | ||
| Q3 25 | $0.13 | — | ||
| Q2 25 | $0.77 | $-0.11 | ||
| Q1 25 | $1.30 | $0.14 | ||
| Q4 24 | $0.90 | $0.22 | ||
| Q3 24 | $1.28 | $0.21 | ||
| Q2 24 | $2.23 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.0M | $209.8M |
| 总债务越低越好 | $348.0M | — |
| 股东权益账面价值 | $1.7B | $2.1B |
| 总资产 | $2.6B | $2.6B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LPXTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $292.0M | $172.9M | ||
| Q3 25 | $316.0M | — | ||
| Q2 25 | $333.0M | $162.2M | ||
| Q1 25 | $256.0M | $140.7M | ||
| Q4 24 | $340.0M | $177.5M | ||
| Q3 24 | $346.0M | $187.5M | ||
| Q2 24 | $317.0M | $152.9M |
总债务LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | $348.0M | $260.0M | ||
| Q3 25 | $348.0M | — | ||
| Q2 25 | $348.0M | $346.0M | ||
| Q1 25 | $348.0M | $330.0M | ||
| Q4 24 | $348.0M | $300.0M | ||
| Q3 24 | $347.0M | $300.0M | ||
| Q2 24 | $347.0M | $319.0M |
股东权益LPXTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.7B | $2.0B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.7B | $2.0B | ||
| Q4 24 | $1.7B | $2.1B | ||
| Q3 24 | $1.7B | $2.1B | ||
| Q2 24 | $1.7B | $2.1B |
总资产LPXTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $2.6B | $2.5B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.7B | $2.6B | ||
| Q1 25 | $2.6B | $2.6B | ||
| Q4 24 | $2.6B | $2.7B | ||
| Q3 24 | $2.6B | $2.7B | ||
| Q2 24 | $2.5B | $2.7B |
负债/权益比LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | 0.20× | 0.13× | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | 0.18× | ||
| Q1 25 | 0.21× | 0.16× | ||
| Q4 24 | 0.21× | 0.14× | ||
| Q3 24 | 0.21× | 0.14× | ||
| Q2 24 | 0.21× | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-8.0M | — |
| 自由现金流率自由现金流/营收 | -1.4% | — |
| 资本支出强度资本支出/营收 | 13.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.0M | — |
8季度趋势，按日历期对齐
经营现金流LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | $67.0M | — | ||
| Q3 25 | $89.0M | — | ||
| Q2 25 | $162.0M | $98.2M | ||
| Q1 25 | $64.0M | $41.1M | ||
| Q4 24 | $105.0M | $84.3M | ||
| Q3 24 | $183.0M | $63.9M | ||
| Q2 24 | $212.0M | $75.5M |
自由现金流LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $94.0M | $93.3M | ||
| Q1 25 | $0 | $31.0M | ||
| Q4 24 | $43.0M | $77.5M | ||
| Q3 24 | $139.0M | $54.7M | ||
| Q2 24 | $176.0M | $57.5M |
自由现金流率LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | -1.4% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 12.5% | 29.4% | ||
| Q1 25 | 0.0% | 9.8% | ||
| Q4 24 | 6.3% | 26.1% | ||
| Q3 24 | 19.3% | 18.9% | ||
| Q2 24 | 21.6% | 18.8% |
资本支出强度LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 12.7% | — | ||
| Q2 25 | 9.0% | 1.5% | ||
| Q1 25 | 8.8% | 3.2% | ||
| Q4 24 | 9.1% | 2.3% | ||
| Q3 24 | 6.1% | 3.2% | ||
| Q2 24 | 4.4% | 5.9% |
现金转化率LPXTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 9.89× | — | ||
| Q2 25 | 3.00× | — | ||
| Q1 25 | 0.70× | 1.82× | ||
| Q4 24 | 1.69× | 2.42× | ||
| Q3 24 | 2.03× | 1.90× | ||
| Q2 24 | 1.32× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
